Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT.

PURPOSE To prospectively assess the utility of perfusion computed tomography (CT) for differentiating minimal from intermediate fibrosis in treatment-naïve patients with chronic hepatitis C virus (HCV) infection. MATERIALS AND METHODS This study was approved by the Institutional Review Board, and informed consent was obtained. Fifty-two patients with treatment-naïve HCV infection underwent perfusion CT and percutaneous liver biopsy on the same day. Portal vein, arterial, and total liver perfusion; mean transit time; and distribution volumes for the right and left liver lobes were measured. Liver samples were scored for fibrosis, and fibrosis area was determined. Differences in quantitative perfusion parameters between patients with minimal fibrosis (score of F1) and those with intermediate fibrosis (score of F2 or F3) were tested. RESULTS In patients with intermediate fibrosis (F2 and F3) compared with those with minimal fibrosis (F1), the portal venous perfusion (87 mL min(-1) 100 mL(-1) +/- 27 [standard deviation] vs 138 mL min(-1) 100 mL(-1) +/- 112, P = .042) and total liver perfusion (107 mL min(-1) 100 mL(-1) +/- 31 vs 169 mL min(-1) 100 mL(-1) +/- 137, P = .02) were significantly decreased, and the mean transit time was significantly increased (16 seconds +/- 4 vs 13 seconds +/- 5, P = .025). At multivariate analysis, only the mean transit time was an independent factor (odds ratio, 1.18; 95% confidence interval: 1.02, 1.37; P = .030). Receiver operating characteristic curve analysis showed that a mean transit time threshold of 13.4 seconds allowed discrimination between minimal and intermediate fibrosis with a sensitivity of 71% and a specificity of 65%. CONCLUSION The results of this study show that perfusion changes occur early during fibrosis in chronic HCV infection and can be detected with perfusion CT. Perfusion CT may help to discriminate minimal from intermediate fibrosis. Mean transit time appears to be the most promising perfusion parameter for differentiating between fibrosis stages, although the large amount of overlap in the measured parameters limits the clinical utility of this test at present.

[1]  J. Villeneuve,et al.  Intrahepatic Circulation in Liver Disease1 , 1986, Seminars in liver disease.

[2]  A K Dixon,et al.  Functional images of hepatic perfusion obtained with dynamic CT. , 1993, Radiology.

[3]  M Kormano,et al.  Liver Perfusion Studied with Ultrafast CT , 1995, Journal of computer assisted tomography.

[4]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[5]  Hepatic perfusion changes in patients with cirrhosis indices of hepatic arterial blood flow. , 1999, Clinical nuclear medicine.

[6]  W. Fleig,et al.  Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. , 1999, Gastroenterology.

[7]  G Brix,et al.  Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images , 1999, Journal of magnetic resonance imaging : JMRI.

[8]  F. Degos,et al.  Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.

[9]  W. Fleig,et al.  Hepatic arterial blood flow velocities: assessment by transcutaneous and intravascular Doppler sonography. , 2000, Journal of hepatology.

[10]  R Materne,et al.  Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. , 2001, AJR. American journal of roentgenology.

[11]  Klaus Haag,et al.  Hepatic arterial buffer response in patients with advanced cirrhosis , 2002, Hepatology.

[12]  T. Asselah,et al.  Fibrosis and disease progression in hepatitis C , 2002, Hepatology.

[13]  B. V. Van Beers,et al.  Assessment of hepatic perfusion parameters with dynamic MRI , 2002, Magnetic resonance in medicine.

[14]  J. Dienstag,et al.  The role of liver biopsy in chronic hepatitis C , 2002, Hepatology.

[15]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[16]  A. Befeler,et al.  Hepatocellular carcinoma: diagnosis and treatment. , 2002, Gastroenterology.

[17]  C. Sempoux,et al.  Capillarization of the sinusoids in liver fibrosis: Noninvasive assessment with contrast‐enhanced MRI in the rabbit , 2003, Magnetic resonance in medicine.

[18]  B. V. Van Beers,et al.  Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. , 2003, Radiology.

[19]  G. Leandro,et al.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. , 2003, Journal of hepatology.

[20]  S. Friedman,et al.  Liver fibrosis -- from bench to bedside. , 2003, Journal of hepatology.

[21]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[22]  T. Roskams,et al.  Cirrhosis reversal: a duel between dogma and myth. , 2004, Journal of hepatology.

[23]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[24]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[25]  Y. Takeda,et al.  Assessment of the severity of liver disease and fibrotic change: the usefulness of hepatic CT perfusion imaging. , 2006, Oncology reports.

[26]  Ralph Sinkus,et al.  Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. , 2007, Radiology.

[27]  Bachir Taouli,et al.  Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. , 2007, AJR. American journal of roentgenology.

[28]  B. V. Van Beers,et al.  Assessment of diffusion‐weighted MR imaging in liver fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.

[29]  D. Brenner,et al.  Computed tomography--an increasing source of radiation exposure. , 2007, The New England journal of medicine.

[30]  Pierre-Yves Boëlle,et al.  Diffusion‐weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C , 2007, Hepatology.

[31]  Steve Halligan,et al.  Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? , 2007, Radiology.

[32]  H. Rusinek,et al.  Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience. , 2008, Radiology.

[33]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[34]  Ralph Sinkus,et al.  Magnetic resonance elastography for the noninvasive staging of liver fibrosis. , 2008, Gastroenterology.

[35]  Eva Herrmann,et al.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. , 2008, Gastroenterology.

[36]  C. Zuiani,et al.  Relevance of b‐values in evaluating liver fibrosis: A study in healthy and cirrhotic subjects using two single‐shot spin‐echo echo‐planar diffusion‐weighted sequences , 2008, Journal of magnetic resonance imaging : JMRI.

[37]  D. Thabut,et al.  Biomarkers of liver fibrosis. , 2008, Advances in clinical chemistry.

[38]  Richard L Ehman,et al.  Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications , 2007, Hepatology.

[39]  Y. Ngo,et al.  Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease , 2009, Hepatology.

[40]  Kazuhiro Katada,et al.  Whole-brain perfusion CT performed with a prototype 256-detector row CT system: initial experience. , 2009, Radiology.

[41]  Willi A Kalender,et al.  Application- and patient size-dependent optimization of x-ray spectra for CT. , 2009, Medical physics.